KFDA approves Eloxatin for stomach cancer

Published: 2003-07-09 06:57:00

Updated: 2003-07-09 06:57:00

The Korea Food and Drug Administration recently announced the expanded approval of Eloxatin (oxaliplatin) injection developed by Sanofi-Synthelabo Inc., for the treatment of patients with irresectable and advanced stomach cancer plus 5-FU and folinic acid, in addition to colorectal cancer.

On July 1998, the KFDA approved Eloxan as the first-line anticancer therapy for use in combination with...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.